HEADER ANTIBIOTIC 29-OCT-18 6MW0 TITLE MLE-PHE-MLE-D-PHE. LINEAR TETRAPEPTIDE RELATED TO PSEUDOXYLALLEMYCIN TITLE 2 A. COMPND MOL_ID: 1; COMPND 2 MOLECULE: MLE-PHE-MLE-D-PHE LINEAR TETRAPEPTIDE RELATED TO COMPND 3 PSEUDOXYLALLEMYCIN A; COMPND 4 CHAIN: A; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: XYLARIA; SOURCE 4 ORGANISM_TAXID: 37991 KEYWDS TETRAPEPTIDE, N-METHYL LEUCINE, PSEUDOXYLALLEMYCIN A, ANTIBIOTIC EXPDTA X-RAY DIFFRACTION AUTHOR A.J.CAMERON,P.W.R.HARRIS,M.A.BRIMBLE,C.J.SQUIRE REVDAT 1 11-SEP-19 6MW0 0 JRNL AUTH A.J.CAMERON,C.J.SQUIRE,A.GERENTON,L.A.STUBBING,P.W.R.HARRIS, JRNL AUTH 2 M.A.BRIMBLE JRNL TITL INVESTIGATIONS OF THE KEY MACROLACTAMISATION STEP IN THE JRNL TITL 2 SYNTHESIS OF CYCLIC TETRAPEPTIDE PSEUDOXYLALLEMYCIN A. JRNL REF ORG.BIOMOL.CHEM. V. 17 3902 2019 JRNL REFN ESSN 1477-0539 JRNL PMID 30941386 JRNL DOI 10.1039/C9OB00227H REMARK 2 REMARK 2 RESOLUTION. 0.78 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 0.78 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 23.02 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 CROSS-VALIDATION METHOD : NONE REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE (F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 41 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 2 REMARK 3 SOLVENT ATOMS : 7 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : NULL REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : NULL REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : NULL REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : NULL REMARK 3 NUMBER OF RESTRAINTS : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 ANGLE DISTANCES (A) : NULL REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : NULL REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : NULL REMARK 3 ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : NULL REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : NULL REMARK 3 SIMILAR ADP COMPONENTS (A**2) : NULL REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : NULL REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: FULL LEAST SQUARES REFINEMENT IN SHELXL REMARK 3 WITH ANISOTROPIC DISPLACEMENT PARAMETERS AND HYDROGENS PLACED IN REMARK 3 RIDING POSITIONS. REMARK 4 REMARK 4 6MW0 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 29-OCT-18. REMARK 100 THE DEPOSITION ID IS D_1000237717. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 13-JUL-18 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : AUSTRALIAN SYNCHROTRON REMARK 200 BEAMLINE : MX2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.71075 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 16M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 4911 REMARK 200 RESOLUTION RANGE HIGH (A) : 0.780 REMARK 200 RESOLUTION RANGE LOW (A) : 23.020 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : 11.50 REMARK 200 R MERGE (I) : 0.05900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 14.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 0.78 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 0.80 REMARK 200 COMPLETENESS FOR SHELL (%) : 92.0 REMARK 200 DATA REDUNDANCY IN SHELL : 10.00 REMARK 200 R MERGE FOR SHELL (I) : 0.56700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: AB INITIO PHASING REMARK 200 SOFTWARE USED: SHELXS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 30.19 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.76 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: METHANOL, WATER, EVAPORATION, REMARK 280 TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 4.14550 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 11.50800 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 10.46550 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 11.50800 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 4.14550 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 10.46550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 70 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 830 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: 0.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 MLE-PHE-MLE-D-PHE. LINEAR TETRAPEPTIDE RELATED TO REMARK 400 PSEUDOXYLALLEMYCIN A. THIS PEPTIDE IS LINEAR, UNLIKE CYCLIC REMARK 400 PSEUDOXYLALLEMYCIN A, AND CONTAINS TERMINAL D-PHE, UNLIKE REMARK 400 PSEUDOXYLALLEMYCIN A THAT CONTAINS PHE. REMARK 400 REMARK 400 THE LINEAR TETRAPEPTIDE RELATED TO PSEUDOXYLALLEMYCIN A IS PEPTIDE- REMARK 400 LIKE, A MEMBER OF ANTIBIOTIC CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: LINEAR TETRAPEPTIDE RELATED TO PSEUDOXYLALLEMYCIN A REMARK 400 CHAIN: A REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 6MVZ RELATED DB: PDB REMARK 900 ALL L- VERSION OF THIS PEPTIDE DBREF 6MW0 A 1001 1004 PDB 6MW0 6MW0 1001 1004 SEQRES 1 A 4 MLE PHE MLE DPN HET MLE A1001 18 HET MLE A1003 18 HET DPN A1004 24 HET MOH A1101 2 HETNAM MLE N-METHYLLEUCINE HETNAM DPN D-PHENYLALANINE HETNAM MOH METHANOL FORMUL 1 MLE 2(C7 H15 N O2) FORMUL 1 DPN C9 H11 N O2 FORMUL 2 MOH C H4 O FORMUL 3 HOH *7(H2 O) LINK C AMLE A1001 N APHE A1002 1555 1555 1.37 LINK C BMLE A1001 N BPHE A1002 1555 1555 1.34 LINK C APHE A1002 N AMLE A1003 1555 1555 1.35 LINK C BPHE A1002 N BMLE A1003 1555 1555 1.34 LINK C AMLE A1003 N ADPN A1004 1555 1555 1.30 LINK C BMLE A1003 N BDPN A1004 1555 1555 1.31 CRYST1 8.291 20.931 23.016 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.120613 0.000000 0.000000 0.00000 SCALE2 0.000000 0.047776 0.000000 0.00000 SCALE3 0.000000 0.000000 0.043448 0.00000 HETATM 1 N AMLE A1001 11.602 8.455 16.491 0.50 4.13 N ANISOU 1 N AMLE A1001 436 429 613 -5 -30 -109 N HETATM 2 N BMLE A1001 11.466 8.479 16.214 0.50 5.89 N ANISOU 2 N BMLE A1001 489 517 1099 27 -138 70 N HETATM 3 CN AMLE A1001 11.460 8.818 15.113 0.50 5.71 C ANISOU 3 CN AMLE A1001 749 569 723 -96 62 55 C HETATM 4 CN BMLE A1001 11.343 8.862 14.809 0.50 6.13 C ANISOU 4 CN BMLE A1001 638 679 875 3 -110 -145 C HETATM 5 CA AMLE A1001 10.306 8.231 17.200 0.50 4.98 C ANISOU 5 CA AMLE A1001 506 588 688 1 31 -150 C HETATM 6 CA BMLE A1001 10.225 8.290 17.023 0.50 5.15 C ANISOU 6 CA BMLE A1001 415 483 942 21 -126 70 C HETATM 7 CB AMLE A1001 10.553 7.749 18.628 0.50 5.85 C ANISOU 7 CB AMLE A1001 725 687 680 227 -54 -104 C HETATM 8 CB BMLE A1001 10.557 7.896 18.466 0.50 6.10 C ANISOU 8 CB BMLE A1001 355 688 1137 96 -53 291 C HETATM 9 CG AMLE A1001 9.296 7.088 19.172 0.50 7.71 C ANISOU 9 CG AMLE A1001 518 1413 823 384 6 65 C HETATM 10 CG BMLE A1001 9.386 7.670 19.495 0.50 6.48 C ANISOU 10 CG BMLE A1001 742 858 715 94 -2 -149 C HETATM 11 CD1AMLE A1001 9.446 6.971 20.701 0.50 10.07 C ANISOU 11 CD1AMLE A1001 927 1751 920 802 27 325 C HETATM 12 CD1BMLE A1001 9.922 7.351 20.868 0.50 9.68 C ANISOU 12 CD1BMLE A1001 633 1888 938 -17 18 182 C HETATM 13 CD2AMLE A1001 9.106 5.643 18.622 0.50 9.48 C ANISOU 13 CD2AMLE A1001 746 1193 1448 -218 9 402 C HETATM 14 CD2BMLE A1001 8.496 6.561 18.922 0.50 8.50 C ANISOU 14 CD2BMLE A1001 652 1275 1112 -238 103 258 C HETATM 15 C AMLE A1001 9.567 9.571 17.083 0.50 5.21 C ANISOU 15 C AMLE A1001 304 652 907 -20 -23 -2 C HETATM 16 C BMLE A1001 9.459 9.627 17.073 0.50 5.17 C ANISOU 16 C BMLE A1001 591 486 769 107 -183 -13 C HETATM 17 O AMLE A1001 10.234 10.633 17.344 0.50 5.59 O ANISOU 17 O AMLE A1001 326 509 1162 8 66 -88 O HETATM 18 O BMLE A1001 9.967 10.609 17.548 0.50 5.99 O ANISOU 18 O BMLE A1001 312 630 1199 99 -192 -147 O